Metagenomi Therapeutics Inc. Common Stock (MGX)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business. Metagenomi is an early-stage genome-editing company. Its lead program, MGX-001, is aimed at hemophilia. There is no approved product, and the financial record is that of a research operation. In fiscal 2025, the year ended 2025-12-31, revenue was $25.2 million and net loss was $87.9 million. In fiscal 2024, revenue was $52.3 million and net loss was $78.1 million. Revenue roughly halved while losses widened. In fiscal Q2 2026, the quarter ended 2026-06-30, the filed figures show no revenue and a net loss of $27.5 million. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $1.2 million and net loss was $23.1 million. That is not a compounding machine. The only possible moat is intellectual property and collaborations, including with Ionis, but I cannot underwrite a wide moat from these numbers. Financial health is weak: trailing free cash flow was -$85.8 million, a negative free cash flow yield of -247.7%, Piotroski 1/9, Altman Z -2.45. Debt to equity is 0.34, and beta is 0.68. At $0.92 on 2026-10-13, market cap is $34.6 million and P/B is 0.31. It looks statistically cheap against book value, but book value can vanish through continued losses. The FairStock score is 44/100. The Lynch category is none because it lost money in each of the last three years. This is speculation, not Graham-style investment. I would need evidence of revenue, cost control, and cash runway before treating it as a bargain.

In plain English: Metagenomi develops gene-editing medicines, including a treatment for hemophilia. The business is not yet profitable, is losing money, and sales have fallen. The stock price is very low compared with its accounting value, but continuing losses and cash burn make it a high-risk situation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer